Benitec Biopharma (NASDAQ:BNTC) Research Coverage Started at SVB Leerink

SVB Leerink began coverage on shares of Benitec Biopharma (NASDAQ:BNTC) in a research report released on Monday, MarketBeat reports. The brokerage issued an outperform rating and a $13.00 target price on the biotechnology company’s stock.

A number of other research firms have also recently commented on BNTC. Piper Sandler initiated coverage on Benitec Biopharma in a research report on Thursday, June 13th. They set an overweight rating and a $30.00 price objective for the company. JMP Securities increased their target price on Benitec Biopharma from $10.00 to $16.00 and gave the stock a market outperform rating in a research report on Monday, April 22nd.

Benitec Biopharma Stock Up 3.1 %

BNTC opened at $9.27 on Monday. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.01. Benitec Biopharma has a one year low of $1.86 and a one year high of $10.88. The business’s fifty day moving average is $8.37 and its two-hundred day moving average is $6.14.

Benitec Biopharma (NASDAQ:BNTC) last posted its earnings results on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that Benitec Biopharma will post -7.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Benitec Biopharma

A hedge fund recently raised its stake in Benitec Biopharma stock. GAMMA Investing LLC raised its stake in Benitec Biopharma Inc. (NASDAQ:BNTC) by 53.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,438 shares of the biotechnology company’s stock after purchasing an additional 1,884 shares during the quarter. GAMMA Investing LLC owned about 0.06% of Benitec Biopharma worth $38,000 at the end of the most recent quarter. Institutional investors and hedge funds own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.